Search results
STOCKS OF LOCAL INTEREST
Clinton Herald, Iowa· 6 days agoMay 20—Adv Auto Parts 72.67 Abbott Labs 103.21 ADM 60.87 Ameriprise 433.10 AutoZone, Inc. 2,924.04 Boeing 186.61 Bank of America 38.82 BP PLC ADR 37.26 ConAgra Foods 30.71 Caterpillar 363.01 ...
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Benzinga via Yahoo Finance· 3 days agoKeytruda (pembrolizumab) is Merck & Co Inc’s (NYSE:MRK) top selling cancer drug. The abstract...
Lilly partners with Aktis, deepening radiopharma investment
BioPharma Dive via Yahoo Finance· 6 days agoBristol Myers Squibb and Novartis, the latter of which has two approved radiopharmaceuticals,...
Tango terminates USP1 inhibitor programme
Clinical Trials Arena via Yahoo Finance· 3 days agoThe company’s market cap stands at $757.5m. Tango also planned to evaluate its therapy in combination with AstraZeneca’s and Merck & Co’s poly-ADP ribose...
Scott Black's Strategic Moves in Q4 2023: Spotlight on WR Berkley Corp
GuruFocus.com via Yahoo Finance· 6 days agoThe Walt Disney Co (NYSE:DIS) with 15,767 shares, representing about 1.3% of the portfolio, valued...
Edward Scolnick
GBH News· 1 day agoEdward Scolnick is director of the Psychiatric Disease Program and the Stanley Center for Psychiatric Research at the Broad Institute and a senior...
Why Merck (MRK) is a Top Momentum Stock for the Long-Term
Zacks via Yahoo Finance· 5 days agoMerck (MRK) Based in Kenilworth, NJ, Merck & Co. boasts more than six blockbuster products in its...
What's the Goal in Treating Type 2 Diabetes?
Medscape· 4 days agoAnne Peters discusses the differences in the newly published American College of Physicians and the American Diabetes Association guidelines for treating...
AltruBio lands up to $225M after shift to immune drug research
BioPharma Dive via Yahoo Finance· 6 days agoTwo of 2023’s largest acquisitions — Roche’s $7.1 billion acquisition of Telavant and Merck & Co.’s...
AstraZeneca’s $80B sales plan leans on cancer drug expansion
BioPharma Dive via Yahoo Finance· 6 days agoImfinzi, the company’s flagship immunotherapy, arrived fifth to market in the U.S. and last year...
